

# Accepted Manuscript

Final results of a phase I study of vorinostat, pegylated liposomal doxorubicin and bortezomib in relapsed or refractory multiple myeloma

Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, David D. Hurd

PII: S2152-2650(16)30921-1

DOI: [10.1016/j.clml.2017.05.007](https://doi.org/10.1016/j.clml.2017.05.007)

Reference: CLML 923

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 2 December 2016

Revised Date: 7 March 2017

Accepted Date: 4 May 2017

Please cite this article as: Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DD, Final results of a phase I study of vorinostat, pegylated liposomal doxorubicin and bortezomib in relapsed or refractory multiple myeloma, *Clinical Lymphoma, Myeloma and Leukemia* (2017), doi: [10.1016/j.clml.2017.05.007](https://doi.org/10.1016/j.clml.2017.05.007).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Final results of a phase I study of vorinostat, pegylated liposomal doxorubicin and bortezomib in relapsed or refractory multiple myeloma.**

Running head: Vorinostat, PLD and bortezomib for myeloma

Peter M. Voorhees<sup>1</sup>, Cristina Gasparetto<sup>2</sup>, Dominic T. Moore<sup>3</sup>, Diane Winans<sup>3</sup>, Robert Z. Orlowski<sup>4</sup>, David D. Hurd<sup>5</sup>

1 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

2 Division of Hematological Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

3 Division of Hematology-Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

4 Department of Lymphoma/Myeloma, the University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

5 Section on Hematology and Oncology, Department of Internal Medicine, the Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA

Address correspondence to:

Peter Voorhees, M.D.

Levine Cancer Institute, Carolinas HealthCare System

1021 Morehead Drive

Charlotte, NC 28204

USA

Tel: 980-442-5219 Fax: 980-442-5241

Email: [peter.voorhees@carolinashealthcare.org](mailto:peter.voorhees@carolinashealthcare.org)

Word Count: 4236 (including Abstract, Acknowledgements and Authorship/Conflict of interest statement)

Figure Count: 2

Download English Version:

<https://daneshyari.com/en/article/5581692>

Download Persian Version:

<https://daneshyari.com/article/5581692>

[Daneshyari.com](https://daneshyari.com)